Etienne L'hermite is a seasoned entrepreneur with a background in international business, trade, and tax law. He is currently the Group CEO of DIAVEIN, a medical device company that specializes in treating vascular diseases. However, his true passion lies in helping those suffering from sickle cell disease, a genetic condition that affects millions worldwide. For the past two years, L'hermite has been dedicated to studying this disease and finding ways to alleviate the painful symptoms associated with it. Alongside a team of doctors in Burkina Faso, he conducted a clinical trial using the DIAVEIN treatment, resulting in promising early results.

Prior to his current role, L'hermite has held various leadership positions in different industries, including serving as CEO of Bioxtal, DIAVEIN, and Theranyx. He has also worked as the COO of BNP Parisbas TOKYO and CEO of FTZ JAPAN.

Overall, Etienne L'hermite is a driven, compassionate individual with a wealth of experience and expertise in entrepreneurship and medical technology.